Division of Rheumatology, Department of Medicine, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
Arthritis Research Canada, Vancouver, British Columbia, Canada.
Nat Rev Rheumatol. 2024 Nov;20(11):712-728. doi: 10.1038/s41584-024-01163-z. Epub 2024 Oct 2.
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently associated with a substantial negative impact on health outcomes. The pathogenesis of neuropsychiatric SLE (NPSLE) remains largely unknown, but a single pathogenic mechanism is unlikely to be responsible for the heterogeneous array of clinical manifestations, and a combination of inflammatory and ischaemic mechanistic pathways have been implicated. Currently, valid and reliable biomarkers for the diagnosis of NPSLE are lacking, and differentiating NPSLE from nervous system dysfunction not caused by SLE remains a major challenge for clinicians. However, correct attribution is essential to ensure timely institution of appropriate treatment. In the absence of randomized clinical trials on NPSLE, current treatment strategies are derived from clinical experience with different therapeutic modalities and their efficacy in the management of other manifestations of SLE or of neuropsychiatric disease in non-SLE populations. This Review describes recent advances in the understanding of NPSLE that can inform diagnosis and management, as well as unanswered questions that necessitate further research.
神经精神性红斑狼疮(SLE)的表现较为常见,且常对健康结果产生重大负面影响。神经精神性 SLE(NPSLE)的发病机制尚不清楚,但单一的发病机制不太可能导致临床表现的异质性,炎症和缺血性机制途径的结合已被牵连。目前,用于 NPSLE 诊断的有效和可靠的生物标志物仍然缺乏,并且将 NPSLE 与非 SLE 引起的神经系统功能障碍区分开来仍然是临床医生面临的主要挑战。然而,正确归因对于确保及时实施适当的治疗至关重要。由于没有关于 NPSLE 的随机临床试验,目前的治疗策略源自不同治疗方式的临床经验,以及它们在 SLE 或非 SLE 人群中的神经精神性疾病的其他表现的管理中的疗效。这篇综述描述了对 NPSLE 的理解的最新进展,这些进展可以为诊断和治疗提供信息,同时也提出了需要进一步研究的未解决问题。